About Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company advancing an emerging class of orally available small molecule drugs known as allosteric modulators, targeting neurological disorders and other indications with significant unmet need. Headquartered in Switzerland, the company combines a proprietary technology platform with a diversified pipeline spanning both clinical and pre-clinical programmes.
Allosteric modulation, the mechanism at the heart of Addex's research, works by binding to sites on a receptor that are distinct from the primary active site. This approach offers potential advantages in selectivity and tolerability compared with conventional orthosteric drug design, making it a focus of growing interest in CNS drug discovery.
The company's pipeline includes Dipraglurant, an mGlu5 negative allosteric modulator being evaluated for post-stroke and traumatic brain injury recovery, alongside ADX71149, an mGlu2 positive allosteric modulator developed in partnership with external collaborators. Two further GABAB positive allosteric modulator programmes address substance use disorder and chronic cough, extending the platform's reach beyond strictly neurological indications into respiratory disease.
Addex supports its development activities through strategic partnerships and collaborations, which play a central role in advancing individual pipeline assets. The company is listed on the SIX Swiss Exchange and files with the SEC, maintaining US American Depositary Share (ADS) holders alongside European shareholders.
Further information is available at addextherapeutics.com.
